EUVIMEDEUVIMED entdecken
Open Access

Antibody response, neutralizing potency, and transplacental antibody transfer following SARS‐CoV ‐2 infection versus mRNA ‐1273, BNT162b2 COVID ‐19 vaccination in pregnancy

Carolynn M Dude iD, Naima T Joseph, Alexandra D Forrest, Hans P Verkerke, Narayanaiah Cheedarla, Sakthivel Govindaraj, Les'Shon S Irby, Kirk A Easley, Alicia K Smith, Sean R Stowell, Andrew Neish, Rama Rao Amara und 4 weitere

International Journal of Gynecology & Obstetrics · 2023-07 · 162 (1) · 154-162

DOI: 10.1002/ijgo.14648 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Gynecology & Obstetrics, online erschienen am 19.01.2023. Verfasst von Carolynn M Dude und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: 2019-nCoV Vaccine mRNA-1273, COVID-19. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINR NIH HHS, NIAID NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To improve our understanding of the immune response, including the neutralization antibody response, following COVID‐19 vaccination in pregnancy.

Methods

This was a prospective cohort study comprising patients with PCR‐confirmed SARS‐CoV‐2 infection and patients who received both doses of mRNA COVID‐19 vaccine (mRNA‐1273, BNT162b2) in pregnancy recruited from two hospitals in Atlanta, GA, USA. Maternal blood and cord blood at delivery were assayed for anti‐receptor binding domain (RBD) IgG, IgA and IgM, and neutralizing antibody. The detection of antibodies, titers, and maternal to fetal transfer ratios were compared.

Results

Nearly all patients had detectable RBD‐binding IgG in maternal and cord samples. The vaccinated versus infected cohort had a significantly greater proportion of cord samples with detectable neutralizing antibody (94% vs. 28%, P < 0.001) and significantly higher transfer ratios for RBD‐specific IgG and neutralizing antibodies with a transfer efficiency of 105% (vs. 80%, P < 0.001) and 110% (vs. 90%, P < 0.001), respectively. There was a significant linear decline in maternal and cord blood RBD‐specific IgG and neutralizing antibody titers as time from vaccination to delivery increased.

Conclusions

Those who receive the mRNA COVID‐19 vaccine mount an immune response that is equivalent to—if not greater than—those naturally infected by SARS‐CoV‐2 during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

2019-nCoV Vaccine mRNA-1273COVID-19FemalePregnancyHumansBNT162 VaccineCOVID-19 VaccinesAntibody FormationProspective StudiesSARS-CoV-2Antibodies, NeutralizingRNA, MessengerImmunoglobulin GAntibodies, ViralVaccination

Stichwörter der Autor:innen

SARS-CoV-2pregnancyreproductive immunityvaccine

Substanzen

2019-nCoV Vaccine mRNA-1273BNT162 VaccineCOVID-19 VaccinesAntibodies, NeutralizingRNA, MessengerImmunoglobulin GAntibodies, Viral

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School Boston, Massachusetts, USA.
  • Joint Program in Transfusion Medicine, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
  • Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.

ORCID-Profile: Carolynn M Dude

Förderung

  • NINR NIH HHS
  • NIAID NIH HHS
  • NICHD NIH HHS
  • NIH HHS
  • ODCDC CDC HHS
  • NIEHS NIH HHS
  • Emory Medical Care Foundation
  • Office of AIDS Research

Zitieren

APA

Dude, C. M., Joseph, N. T., Forrest, A. D., Verkerke, H. P., Cheedarla, N., Govindaraj, S., Irby, L. S., Easley, K. A., Smith, A. K., Stowell, S. R., Neish, A., Amara, R. R., Jamieson, D. J., Dunlop, A. L., Badell, M. L., & Velu, V. (2023). Antibody response, neutralizing potency, and transplacental antibody transfer following SARS‐CoV ‐2 infection versus mRNA ‐1273, BNT162b2 COVID ‐19 vaccination in pregnancy. International Journal of Gynecology & Obstetrics, 162(1), 154-162. https://doi.org/10.1002/ijgo.14648

Vancouver

Dude CM, Joseph NT, Forrest AD, Verkerke HP, Cheedarla N, Govindaraj S, et al. Antibody response, neutralizing potency, and transplacental antibody transfer following SARS‐CoV ‐2 infection versus mRNA ‐1273, BNT162b2 COVID ‐19 vaccination in pregnancy. International Journal of Gynecology & Obstetrics. 2023;162(1):154-162. doi:10.1002/ijgo.14648

BibTeX
@article{Dude2023,
  author = {Dude, Carolynn M and Joseph, Naima T and Forrest, Alexandra D and Verkerke, Hans P and Cheedarla, Narayanaiah and Govindaraj, Sakthivel and Irby, Les'Shon S and Easley, Kirk A and Smith, Alicia K and Stowell, Sean R and Neish, Andrew and Amara, Rama Rao and Jamieson, Denise J and Dunlop, Anne L and Badell, Martina L and Velu, Vijayakumar},
  title = {Antibody response, neutralizing potency, and transplacental antibody transfer following SARS‐CoV ‐2 infection versus mRNA ‐1273, BNT162b2 COVID ‐19 vaccination in pregnancy},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2023},
  volume = {162},
  number = {1},
  pages = {154--162},
  doi = {10.1002/ijgo.14648}
}
Kostenlos starten →